Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South Korea Financing Policy

Will Downsized Korean Biopharma Investment Fund Launch Successfully This Time?

Weak But Improving Sentiment

  • News

Executive Summary

Given that previously announced similar programs failed to attract strong investor interest, South Korea is set to create a new biopharma fund but of a smaller target size and lower qualifying thresholds as it continues to support industry development.

You may also be interested in...



Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.

Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender

South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.

Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy

Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.

Table

View full table

Topics

Tags:
South Korea Financing Policy
Latest Headlines

Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer

What Verona Needs To Make COPD Drug Ensifentrine A Success

Biopharma’s Must-Know Q4 Catalysts

Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness

See All
UsernamePublicRestriction

Register

SC148999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By